Tim Kanters (1983) studied Economics at Utrecht University. In 2007 he obtained a Master’s degree in Economics & Geography at this university and in 2008 he obtained a Master’s degree in Health Economics at Erasmus University Rotterdam. Since 2008, he works as a scientific researcher at the Institute for Medical Technology Assessment. His promotion research comprises the assessment of cost-effectiveness of therapies in orphan diseases. The main focus is on the cost-effectiveness of enzyme replacement therapy in Pompe disease, a rare metabolic disease.
T.A. Kanters, C.L.P. Van de Ree, M.A.C. De Jongh, T. Gosens & L. Hakkaart-van Roijen (2020). Burden of illness of hip fractures in elderly Dutch patients. Archives of Osteoporosis, 15 (11). doi: 10.1007/s11657-019-0678-y
T.A. Kanters, W.K. Redekop, M.P.M.H. Rutten - van Molken, M.E. Kruijshaar, D. Güngör, A.T. van der Ploeg & L. Hakkaart-van Roijen (2015). A conceptual disease model for adult Pompe disease. Orphanet Journal of Rare Diseases, 10:112. doi: 10.1186/s13023-015-0334-6
T.A. Kanters, A. Steenhoek & L. Hakkaart-van Roijen (2014). Orphan drugs expenditure in the Netherlands in the period 2006-2012. Orphanet Journal of Rare Diseases, 9:154. doi: 10.1186/s13023-014-0154-0
T.A. Kanters, A.T. van der Ploeg, W.B.F. Brouwer & L. Hakkaart-van Roijen (2013). The impact of informal care for patients with Pompe disease: An application of the CarerQol instrument. Molecular Genetics and Metabolism, 110 (3), 281-286. doi: 10.1016/j.ymgme.2013.07.020
T.A. Kanters, I. Plug, M.P.M.H. van Molken, W.K. Redekop, A.T. van der Ploeg & L. Hakkaart-van Roijen (2013). Cost-effectiveness of enzyme replacement therapy (ERT) with alglucosidase alfa in classic-infantile patients with Pompe disease. Value in Health, 16 (7), A384-A384. doi: 10.1016/j.jval.2013.08.353